Trial Profile
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 18 Jul 2017 New trial record